Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

However, a new class of medications, GLP-1 agonists, originally designed for ... studies reveal a significant overlap between the brain mechanisms driving overeating and substance dependence.

GLP-1 receptor agonists work on GLP-1 receptors ... As a result, "the exact mechanism of the way these medications work is not fully established," he says. This isn’t the first study to find ...

The reductions in addictive behaviors are also encouraging and are consistent with the role of GLP-1 receptors in the ... Al-Aly noted the mechanisms with kidney stone formation are very different ...